Breast Cancer

Biomarker testing looks for genes, proteins and other markers in your cancer that can help your care team choose the most effective treatment for you.

The FDA approved Revtorpyk with fulvestrant, with or without Ibrance, for certain patients with advanced HR-positive, HER2-negative breast cancer.

ASCO 2026 findings and patient stories show how GLP-1 drugs improve metabolic health and potentially transform breast cancer survivorship.

Catina Pitzen, BSN, RN, of Eisai US, leads Columbus P.ink Day, helping breast cancer survivors transform surgical scars into meaningful tattoo art.

FDA approves Trodelvy alone or with Keytruda for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer.

A breast cancer survivor recalls how her phoenix tattoo, chosen years before diagnosis, became a lasting symbol of resilience, survival, and hope.

"Losing friends to metastatic breast cancer brings cumulative grief. Self-care, community, and honoring memories can help you cope with repeated loss." -Martha Carlson

New ASCO data show a TNBC drug combo works for nearly all patients no matter their tumor's genetic profile.

A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating chemotherapy and hair loss.

A breast cancer survivor honors her brother’s legacy 50 years after his death by updating her donor registry status to support vital cancer research.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive patient if it is cancer.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

I thought I understood breast cancer, until a routine conversation at the pharmacy changed everything.

ASCO 2026: Telephone-based weight loss significantly improves physical function and mental health in patients with breast cancer patients who are overweight or obese.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

OPTIMA trial data at ASCO 2026 shows a 50-gene test helps patients with high-risk breast cancer avoid unnecessary and toxic chemotherapy treatments.

Discover five breakthrough breast cancer studies disrupting oncology as global research teams unveil practice-changing data at ASCO 2026 in Chicago.

An inspiring BRCA2 survivor shares her mastectomy journey, launching the Dear Body Project to help women find healing, self-love and community.

Discover how mastectomy-induced sensation loss impacts body image and intimacy, and learn how breast cancer survivors can advocate for their recovery.

A BRCA2-positive previvor shares her 20-year journey, offering empowering advice and community support for those navigating genetic mutation news.

A retired teacher’s plans for "Act II" are derailed by a breast cancer diagnosis, bringing an onslaught of appointments and a double mastectomy.

CURE editor-in-chief Dr. Joshua Sabari explores how ctDNA liquid biopsies could transform breast cancer care while balancing costs and patient anxiety.

FDA approved Datroway for unresectable or metastatic triple-negative breast cancer not eligible for PD-1 or PD-L1 therapy with PFS, OS and response rates vs chemotherapy.